The United States of America, as Represented by the Secretary, Department of Health and Human Services

Bristol-Myers Squibb Compnay

Exelixis, Inc.

Astex Therapeutics Limited

Matthew V Lorenzi

Toru Miki

John N Feder

Marco Gottardis

Liana M Lee

Donald G Jackson

Gregory D Plowman

Ricardo Attar

Lori Friedman

Helen Louise Francis-Lang

David K Bol

Marcia Belvin

Roel P Funke

Roberto Weinmann

Jayaprakash Karkera

Danxi Li

Suso Jesus Platero

Thomas Spires

Dan You

Rolf Peter Ryseck

Raluca Verona

Lata Jayaraman

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

FGFR/PD-1 combination therapy for the treatment of cancer

The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.

Human histone deacetylase, HDAC9c

A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.

Fibroblast growth factor receptor activating gene 1 and related compositions and methods

Polynucleotides encoding human histone deacetylase HDAC9c

Methods for determining whether a test agent inhibits a 17&#x3b2;-HSD3, the methods comprising: obtaining a recombinant host cell that expresses the 17&#x3b2;-HSD3; obtaining a reaction mixture comprising the 17&#x3b2;-HSD3, androstenedione, and the test agent; measuring the amount of testosterone in the reaction mixture by a scintillation proximity assay (SPA) using SPA beads conjugated with a testosterone-specific antibody, wherein when the amount of testosterone is lower in the presence of a test agent than in the absence of the test agent, the test agent is identified as an inhibitor of the 17&#x3b2;-HSD3.

Methods for identifying or screening for agents that modulate 17&#x3b2;-HSD3

Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.

PRMTs as modifiers of the p53 pathway and methods of use

Fibroblast growth factor receptor activating gene I and related compositions and methods

A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.

A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.

Growing community of inventors

Philadelphia, PA, United States of America

Matthew V Lorenzi